Alexandre T.J. Maria

Dr. Alexandre T.J. Maria

Internal Medicine & Onco-Immunology (MedI<sup>2</sup>O), Institute for Regenerative Medicine and Biotherapy, Montpellier University Hospital, Montpellier, France
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2016 in Journal of Autoimmunity
Verified
Journal Article
Closed access
AMAlexandre T.J. Maria
Alexandre T.J. Maria
KTKarine Toupet
Karine Toupet
MMMarie Maumus
Marie Maumus
GFGuillaume Fonteneau
Guillaume Fonteneau
AQAlain Le Quellec
Alain Le Quellec
Daniele NoelDaniele Noel
Daniele Noel

1 January 2021 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
PGPhilippe Guilpain
Philippe Guilpain
CBClément Le Bihan
Clément Le Bihan
VFVincent Foulongne
Vincent Foulongne
PTPatrice Taourel
Patrice Taourel
NPNathalie Pansu
Nathalie Pansu
VMVincent Le Moing
Vincent Le Moing

6 March 2023 in JHEP Reports
Verified
Journal Article
Open access
LHLina Hountondji
Lina Hountondji
CMChristophe Ferreira De Matos
Christophe Ferreira De Matos
FLFanny Lebossé
Fanny Lebossé
XQXavier Quantin
Xavier Quantin
CLCandice Lesage
Candice Lesage
LMLucy Meunier
Lucy Meunier
Immune checkpoint inhibitors (ICIs) have changed the landscape of cancer therapy. Liver toxicity occurs in up to 25% of patients treated with ICIs. The aim of our study was to describe the different clinical patterns of ICI-induced hepatitis and to assess their outcome. We conducted a retrospective observational study of patients with checkpoint inhibitor-induced liver injury (CHILI) discussed in multidisciplinary meetings between December 2018 and March 2022 in three French centres specialised in ICI toxicity management (Montpellier, Toulouse, Lyon). The hepatitis clinical pattern was analysed by the ratio of serum alanine aminotransferase (ALT) and alkaline phosphatase (ALP) (R value = (ALT/ULN)/(ALP/ULN)) for characterisation as cholestatic (R ≤2), hepatocellular (R ≥5), or mixed (2 <R <5). We included 117 patients with CHILI. The clinical pattern was hepatocellular in 38.5%, cholestatic in 36.8%, and mixed in 24.8% of patients. High-grade hepatitis severity (grade ≥3 according to the Common Terminology Criteria for Adverse Events system) was significantly associated with the hepatocellular hepatitis (p <0.05). No cases of severe acute hepatitis were reported. Liver biopsy was performed in 41.9% of patients: granulomatous lesions, endothelitis, or lymphocytic cholangitis were described. Biliary stenosis occurred in eight patients (6.8%) and was significantly more frequent in the cholestatic clinical pattern (p < 0.001). Steroids alone were mainly administered to patients with a hepatocellular clinical pattern (26.5%), and ursodeoxycholic acid was more frequently used in the cholestatic pattern (19.7%) than in the hepatocellular or mixed clinical pattern (p <0.001). Seventeen patients improved without any treatment. Among the 51 patients (43.6%) rechallenged with ICIs, 12 (23.5%) developed CHILI recurrence. This large cohort indicates the different clinical patterns of ICI-induced liver injury and highlights that the cholestatic and hepatocellular patterns are the most frequent with different outcomes. ICIs can induce hepatitis. In this retrospective series, we report 117 cases of ICI-induced hepatitis, mostly grades 3 and 4. We find a similar distribution of the different patterns of hepatitis. ICI could be resumed without systematic recurrence of hepatitis.

30 March 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
RGRadjiv Goulabchand
Radjiv Goulabchand
AHAssia Hafidi
Assia Hafidi
PPPhilippe Van de Perre
Philippe Van de Perre
IMIngrid Millet
Ingrid Millet
AMAlexandre T.J. Maria
Alexandre T.J. Maria
PGPhilippe Guilpain
Philippe Guilpain
Mastitis frequently affects women of childbearing age. Of all the pathological breast conditions requiring specific management, autoimmune mastitis is in the third position after infection and breast cancer. The aim of this literature review was to make a comprehensive description of autoimmune diseases targeting the mammary gland. Four main histological patterns of autoimmune mastitis are described: (i) lymphocytic infiltrates; (ii) ductal ectasia; (iii) granulomatous mastitis; and (iv) vasculitis. Our literature search found that all types of autoimmune disease may target the mammary gland: organ-specific diseases (diabetes, thyroiditis); connective tissue diseases (such as systemic erythematosus lupus or Sjögren’s syndrome); vasculitides (granulomatosis with polyangiitis, eosinophilic granulomatosis with polyangiitis, giant cell arteritis, polyarteritis nodosa, Behçet’s disease); granulomatous diseases (sarcoidosis, Crohn’s disease); and IgG4-related disease. Cases of breast-specific autoimmune diseases have also been reported, including idiopathic granulomatous mastitis. These breast-limited inflammatory diseases are sometimes the first symptom of a systemic autoimmune disease. Although autoimmune mastitis is rare, it is probably underdiagnosed or misdiagnosed. Early diagnosis may allow us to detect systemic diseases at an earlier stage, which could help to initiate a prompt, appropriate therapeutic strategy. In case of suspected autoimmune mastitis, we hereby propose a diagnostic pathway and discuss the potential pathophysiological pathways leading to autoimmune breast damage.

26 March 2024 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
CCCamille Cosson
Camille Cosson
RRRomane Riou
Romane Riou
DPDanish Patoli
Danish Patoli
TNTingting Niu
Tingting Niu
ARAmaury Rey
Amaury Rey
BPBenedicte Py
Benedicte Py
NLRP3-associated autoinflammatory disease is a heterogenous group of monogenic conditions caused by NLRP3 gain-of-function mutations. The poor functional characterization of most NLRP3 variants hinders diagnosis despite efficient anti-IL-1 treatments. Additionally, while NLRP3 is controlled by priming and activation signals, gain-of-functions have only been investigated in response to priming. Here, we characterize 34 NLRP3 variants in vitro, evaluating their activity upon induction, priming, and/or activation signals, and their sensitivity to four inhibitors. We highlight the functional diversity of the gain-of-function mutants and describe four groups based on the signals governing their activation, correlating partly with the symptom severity. We identify a new group of NLRP3 mutants responding to the activation signal without priming, associated with frequent misdiagnoses. Our results identify key NLRP3 residues controlling inflammasome activity and sensitivity to inhibitors, and antagonistic mechanisms with broader efficacy for therapeutic strategies. They provide new insights into NLRP3 activation, an explanatory mechanism for NLRP3-AID heterogeneity, and original tools for NLRP3-AID diagnosis and drug development.

25 August 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
FCFlorence Chaudot
Florence Chaudot
Pascal SèvePascal Sève
Pascal Sève
ARAntoine Rousseau
Antoine Rousseau
AMAlexandre T.J. Maria
Alexandre T.J. Maria
PFP. Fournié
P. Fournié
YJYvan JAMILLOUX
Yvan JAMILLOUX
Ocular immunotherapy-related adverse events (IRAEs), although rare, can be sight-threatening. Our objective was to analyze ocular IRAEs diagnosed in France from the marketing of immune checkpoint inhibitors (ICPIs) until June 2021 and to review the literature. We collected the cases of 28 patients (36 ocular IRAEs), occurring after an average of 17 weeks (±19). Forty-six percent of patients were treated for metastatic melanoma. Anti-PD1 agents were responsible for 57% of the IRAEs. Anterior uveitis was the most common (44%), followed by panuveitis (28%). Of 25 uveitis cases, 80% were bilateral and 60% were granulomatous. We found one case with complete Vogt-Koyanagi–Harada syndrome and one case of birdshot retinochoroidopathy. The other IRAEs were eight ocular surface disorders, one optic neuropathy, and one inflammatory orbitopathy. Seventy percent of the IRAEs were grade 3 according to the common terminology of AEs. ICPIs were discontinued in 60% of patients and 50% received local corticosteroids alone. The literature review included 230 uveitis cases, of which 7% were granulomatous. The distributions of ICPIs, cancer, and type of uveitis were similar to our cohort. Ocular IRAEs appeared to be easily controlled by local or systemic corticosteroids and did not require routine discontinuation of ICPIs. Further work is still warranted to define the optimal management of ocular IRAEs.